Genomic Strategies Target Bacteria

Bacteria are winning, and infectious disease doctors are worried. Disease-causing microbes are increasingly able to defeat the best antimicrobial drugs available. No "superbug" has yet emerged, resistant to all antibiotics and therefore untreatable. But that day may not be too far off. "There's increasing panic among infectious disease specialists,'' admits Jonathan Blum, a clinician and researcher at Harvard Medical School. Particularly worrisome to those specialists is a strain k

Written byBilly Goodman
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Bacteria are winning, and infectious disease doctors are worried. Disease-causing microbes are increasingly able to defeat the best antimicrobial drugs available. No "superbug" has yet emerged, resistant to all antibiotics and therefore untreatable. But that day may not be too far off.

"There's increasing panic among infectious disease specialists,'' admits Jonathan Blum, a clinician and researcher at Harvard Medical School.

Particularly worrisome to those specialists is a strain known as methicillin-resistant Staphylococcus aureus (MRSA), which occurs widely in hospitals and is resistant to all antibiotics save one, vancomycin. Staph aureus is a common skin bacterium that can cause deadly infections when it enters the body, such as after surgery. Recently, a few cases of MRSA that show intermediate resistance to vancomycin have appeared. If true resistance develops, Staph aureus infections might be uncurable, and therefore fatal.

As multiply resistant pathogenic microbes become more common, development of antibiotics has lagged behind. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies